how many crypto Featured

First of all, it is diet pills. The company's smegliptide has been in phase III clinical trials, and it is expected to take a share in the domestic market, especially in the international market in the future. At the same time, the cumulative effect of liraglutide has greatly improved the fundamentals of Hanyu Pharmaceutical. It is crucial to sell it in the American market and share the profits in the later period, which is the most imaginative potential benefit.Hanyu Pharmaceutical announced last night that the company has once again received the purchase demand order from American partner Hikma, and Hikma intends to purchase liraglutide injection (generic drug) with the amount of 10.5624 million US dollars (about RMB 77 million, including tax) from the company. As of the disclosure date of the announcement, the accumulated contract amount signed by the company and Hikma is about 338 million yuan! This is undoubtedly a shot in the arm for Hanyu Pharmaceutical, whose performance has been declining for many years.I haven't paid attention to my friends yet. Click on the top right corner to pay attention, share wealth and wisdom, and be a long-term winner!

Secondly, from a technical point of view, since the bottom in 2021, the quarterly and monthly lines have shown that there are large funds operating in it for a long time, and the long-term moving average in June has recently turned upward, and the weekly line also shows signs of platform breakthrough.【 Expanded Title 】 Hanyu Pharmaceutical, Will It Be the Next Jiu 'an Medical Care?

First of all, it is diet pills. The company's smegliptide has been in phase III clinical trials, and it is expected to take a share in the domestic market, especially in the international market in the future. At the same time, the cumulative effect of liraglutide has greatly improved the fundamentals of Hanyu Pharmaceutical. It is crucial to sell it in the American market and share the profits in the later period, which is the most imaginative potential benefit.Secondly, from a technical point of view, since the bottom in 2021, the quarterly and monthly lines have shown that there are large funds operating in it for a long time, and the long-term moving average in June has recently turned upward, and the weekly line also shows signs of platform breakthrough.First of all, it is diet pills. The company's smegliptide has been in phase III clinical trials, and it is expected to take a share in the domestic market, especially in the international market in the future. At the same time, the cumulative effect of liraglutide has greatly improved the fundamentals of Hanyu Pharmaceutical. It is crucial to sell it in the American market and share the profits in the later period, which is the most imaginative potential benefit.